These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29385311)

  • 1. Viral eradication and fibrosis resolution in post-liver transplant cholestatic hepatitis C virus.
    Mauro E; Crespo G; Montironi C; Londoño MC; Díaz A; Forns X; Navasa M
    Liver Transpl; 2018 May; 24(5):703-707. PubMed ID: 29385311
    [No Abstract]   [Full Text] [Related]  

  • 2. Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus.
    Doughty AL; Painter DM; McCaughan GW
    J Hepatol; 2000 Jan; 32(1):126-34. PubMed ID: 10673077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplant recurrent hepatitis C: immunohistochemical detection of hepatitis C virus core antigen and possible pathogenic implications.
    Pessôa MG; Alves VA; Wakamatsu A; Gomes JG; Maertens G; van der Borght B; Kim M; Ferrell L; Wright TL
    Liver Int; 2008 Jul; 28(6):807-13. PubMed ID: 18422936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
    Verna EC; Saxena V; Burton JR; O'Leary JG; Dodge JL; Stravitz RT; Levitsky J; Trotter JF; Everson GT; Brown RS; Terrault NA;
    Transplantation; 2015 Aug; 99(8):1644-51. PubMed ID: 25715116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
    Satapathy SK; Fiel MI; Vanatta JM; Del Rio Martin J; Schiano TD
    Exp Clin Transplant; 2013 Dec; 11(6):522-9. PubMed ID: 23901801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.
    Vukotic R; Conti F; Fagiuoli S; Morelli MC; Pasulo L; Colpani M; Foschi FG; Berardi S; Pianta P; Mangano M; Donato MF; Malinverno F; Monico S; Tamè M; Mazzella G; Belli LS; Viganò R; Carrai P; Burra P; Russo FP; Lenci I; Toniutto P; Merli M; Loiacono L; Iemmolo R; Degli Antoni AM; Romano A; Picciotto A; Rendina M; Andreone P;
    J Viral Hepat; 2017 Oct; 24(10):858-864. PubMed ID: 28370880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
    Martini S; Sacco M; Strona S; Arese D; Tandoi F; Dell Olio D; Stradella D; Cocchis D; Mirabella S; Rizza G; Magistroni P; Moschini P; Ottobrelli A; Amoroso A; Rizzetto M; Salizzoni M; Saracco GM; Romagnoli R
    Liver Int; 2017 Jan; 37(1):62-70. PubMed ID: 27344058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation.
    Schluger LK; Sheiner PA; Thung SN; Lau JY; Min A; Wolf DC; Fiel I; Zhang D; Gerber MA; Miller CM; Bodenheimer HC
    Hepatology; 1996 May; 23(5):971-6. PubMed ID: 8621177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review.
    Tronina O; Ślubowska K; Mikołajczyk-Korniak N; Komuda-Leszek E; Wieczorek-Godlewska R; Łągiewska B; Pacholczyk M; Lisik W; Kosieradzki M; Durlik M
    Transplant Proc; 2017; 49(6):1409-1418. PubMed ID: 28736015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation.
    Shackel NA; Jamias J; Rahman W; Prakoso E; Strasser SI; Koorey DJ; Crawford MD; Verran DJ; Gallagher J; McCaughan GW
    Liver Transpl; 2009 Jul; 15(7):709-18. PubMed ID: 19562704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable short-term outcome of hepatitis C virus-positive liver graft with bridging fibrosis: A plea for very early viral eradication.
    Martini S; Salizzoni M; David E; Tandoi F; Fonio P; Delsedime L; Strona S; Dell Olio D; Saracco GM; Romagnoli R
    Hepatology; 2017 Jun; 65(6):2116-2118. PubMed ID: 27981614
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
    Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal assessment of hepatic fibrosis in responders to direct-acting antivirals for recurrent hepatitis C after liver transplantation using noninvasive methods.
    Omar H; Said M; Eletreby R; Mehrez M; Bassam M; Abdellatif Z; Hosny A; Megawer S; El Amir M; Yosry A
    Clin Transplant; 2018 Aug; 32(8):e13334. PubMed ID: 29935046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
    Beig J; Orr D; Harrison B; Gane E
    Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholestatic hepatitis C in liver allografts.
    Taga SA; Washington MK; Terrault N; Wright TL; Somberg KA; Ferrell LD
    Liver Transpl Surg; 1998 Jul; 4(4):304-10. PubMed ID: 9649645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder.
    Al Nahdi N; Ford JA; Greanya ED; Harrigan JA; Tse I; Steinbrecher UP; Erb SR; Yoshida EM
    Ann Hepatol; 2013; 12(1):156-60. PubMed ID: 23293209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hepatitis Aggressiveness Score (HAS): a novel classification system for post-liver transplantation recurrent hepatitis C.
    Moreira RK; Salomao M; Verna EC; Brown RS; Lefkowitch JH
    Am J Surg Pathol; 2013 Jan; 37(1):104-13. PubMed ID: 23060356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence.
    J S Cross T; Jothimani D; Heneghan MA; Harrison PM
    Clin Transplant; 2011; 25(3):345-51. PubMed ID: 21517974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.